To scroll text in this page

Global Navigation

Investor Relations

Start of the main text

Sales of Major Products

Consolidated sales of global products [IFRS]

(billion yen)
  FY2015 FY2016
XTANDI 252.1 252.1
  US 148.4 131.7
  Ex-US 103.7 120.4
  Japan 26.2 23.4
    Americas(Ex-US) 4.5 7.7
    EMEA* 70.7 85.3
    Asia and Oceania 2.4 4.0
Vesicare 135.6 116.1
    Japan 26.5 25.6
    Americas 63.7 53.1
    EMEA* 39.8 32.0
    Asia and Oceania 5.3 5.0
Betanis / Myrbetriq / BETMIGA 81.7 98.8
    Japan 21.2 25.9
    Americas 45.7 55.3
    EMEA* 13.4 14.1
    Asia and Oceania 1.4 3.5
Prograf 203.6 186.2
    Japan 49.8 48.8
    Americas 34.6 27.3
    EMEA* 77.9 70.1
    Asia and Oceania 38.4 37.3
    Exports to third parties 2.8 2.6
Harnal 53.4 47.7
Funguard/
Mycamine
41.6 40.3
Eligard 17.6 15.9

*Europe, the Middle East and Africa

Note: Sales of products in Japan are shown in a gross sales basis.


Consolidated Sales of Other Products [IFRS]

Rx Sales in Japan

(billion yen)
  FY2015 FY2016
Micardis
   Micombi
   Micamlo
97.2 93.2
Celecox 46.6 47.6
Symbicort 37.4 39.3
Lipitor 30.9 23.2
Myslee 17.9 147
Bonoteo 14.1 13.8
Gaster 14.7 10.7
Geninax 10.8 10.1
Suglat 7.3 9.5

Note: Sales of products are shown in a gross sales basis.


RX Sales in Americas and Europe

(billion yen)
  FY2016 FY2016
Scan*
(Americas)
  76.2 71.5
Tarceva US 33.8 25.8
Ex-US 13.0 9.4

* Adenoscan + Lexiscan

Main Text end
Local Navigation
Local Navigation end
Related Links